Arcutis Biotherapeutics, Inc. (ARQT) Stock AnalysisARQTStock AnalysisArcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arcutis Biotherapeutics Inc is currently priced at $23.78, which is significantly below the analyst price targets of $34 and $35, indicating potential upside. However, the RSI is at a low 22.653, suggesting the stock is oversold, and there is a recent trend of insider selling increasing by 106.52%, which raises concerns about confidence in the stock. Given these factors, while there is potential for recovery, the current market sentiment and insider activity suggest holding rather than buying.